Biovica International AB (publ) Cash Flow Conversion Efficiency

Latest as of July 2025: -0.670x

Biovica International AB (publ) cash flow conversion efficiency. Based on the latest financial reports, Biovica International AB (publ) (BIOVIC-B) has a cash flow conversion efficiency ratio of -0.670x as of July 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-17.20 Million ≈ $-1.85 Million USD) by net assets (Skr25.68 Million ≈ $2.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Biovica International AB (publ) (2015–2025)

Cash flow conversion efficiency of Biovica International AB (publ) from 2015 to 2025. This chart illustrates how Biovica International AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View BIOVIC-B stock price for real-time trading data and today's change.

Biovica International AB (publ) Cash Flow Conversion Ratio Explained

Biovica International AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Biovica International AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biovica International AB (publ) ranked by their cash flow conversion efficiency. Also see BIOVIC-B market cap overview for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
VR Resources Ltd
V:VRR
-0.111x
elumeo SE
XETRA:ELB
0.087x
Agrimin Ltd
AU:AMN
-0.039x
Invert Graphite Limited
AU:IVG
-0.141x
Priceworth International Bhd
KLSE:7123
-0.039x
Global Engine Group Holding Limited Ordinary Shares
NASDAQ:GLE
-0.124x
Western Mines Group Ltd
AU:WMG
0.019x
Narmada Agrobase Limited
NSE:NARMADA
0.002x

Annual Cash Flow Conversion Efficiency for Biovica International AB (publ) (2015–2025)

The table below shows the annual cash flow conversion efficiency of Biovica International AB (publ) from 2015 to 2025. Review Biovica International AB (publ) free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-04-30 Skr43.21 Million
≈ $4.65 Million
Skr-85.37 Million
≈ $-9.19 Million
-1.976x -66.65%
2024-04-30 Skr96.64 Million
≈ $10.40 Million
Skr-114.58 Million
≈ $-12.33 Million
-1.186x -73.67%
2023-04-30 Skr138.64 Million
≈ $14.92 Million
Skr-94.64 Million
≈ $-10.18 Million
-0.683x -62.51%
2022-04-30 Skr124.09 Million
≈ $13.35 Million
Skr-52.13 Million
≈ $-5.61 Million
-0.420x -123.00%
2021-04-30 Skr182.66 Million
≈ $19.66 Million
Skr-34.41 Million
≈ $-3.70 Million
-0.188x +40.54%
2020-04-30 Skr78.22 Million
≈ $8.42 Million
Skr-24.78 Million
≈ $-2.67 Million
-0.317x +8.13%
2019-04-30 Skr52.10 Million
≈ $5.61 Million
Skr-17.97 Million
≈ $-1.93 Million
-0.345x -70.81%
2018-04-30 Skr73.71 Million
≈ $7.93 Million
Skr-14.88 Million
≈ $-1.60 Million
-0.202x -66.66%
2017-04-30 Skr91.55 Million
≈ $9.85 Million
Skr-11.09 Million
≈ $-1.19 Million
-0.121x +67.11%
2016-04-30 Skr25.48 Million
≈ $2.74 Million
Skr-9.38 Million
≈ $-1.01 Million
-0.368x -432.23%
2015-04-30 Skr8.32 Million
≈ $894.93K
Skr922.00K
≈ $99.22K
0.111x --

About Biovica International AB (publ)

ST:BIOVIC-B Sweden Biotechnology
Market Cap
$10.07 Million
Skr93.60 Million SEK
Market Cap Rank
#26917 Global
#576 in Sweden
Share Price
Skr0.34
Change (1 day)
-2.30%
52-Week Range
Skr0.28 - Skr0.60
All Time High
Skr66.10
About

Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more